必威手机APP医疗保健提供者迫切需要了解用于治疗Covid-19的各种疗法的安全性和功效。在大流行的早期，FDA已授予紧急授权使用羟氯喹（HCQ），许多提供者单独使用它和/或与Azithromycin（AZM）结合使用。
Both drugs, however, have the potential to cause life-threatening arrhythmias. There was, therefore, a critical need to know what risk the combination posed in short-term use to treat COVID-19 patients. To address this need, IQVIA experts conducted a global observational study utilizingreal world datato provide immediate answers for treatment decisions.
Download our case study to learn:
- Details on the round-the-clock virtual meeting, including the design and execution of multiple simultaneous studies
- Results of the eight observational studies, including examination of the safety of using HCQ alone and in combination with AZM in rheumatoid arthritis patients
- 为什么IQVIA研究 - THON已成为创建正在进行的Covid-19研究组的催化剂